| 產(chǎn)品名稱 | Regorafenib - BAY 73-4506 | Stivarga |
| 產(chǎn)品貨號 | Axon 1678 CAS [755037-03-7] MF C21H15ClF4N4O3MW 482.82 Purity: 98% Soluble in DMSO Description An oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition References Certificates Categories Extra info SM Wilhelm et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer. 2011, 129(1), 245-55. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR MAPK c-KIT RTK class III and IV; EC 2.7.10.1 RAF Multi-kinase RTK inhibitor Chemical name 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide Parent CAS No. [755037-03-7] Order Size Unit Price Stock 5 mg €75.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Regorafenib - BAY 73-4506 | StivargaAxon 1678 CAS [755037-03-7] MF C21H15ClF4N4O3
Description
An oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Multi-kinase RTK inhibitor
Chemical name4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide Parent CAS No.[755037-03-7] |
| 產(chǎn)品資料 |
